framingham teaching dataA subset of the framingham teaching dataset containing the following changes:
removal of all observations where PERIOD == 2 or PERIOD == 3 (i.e. keep only PERIOD == 1)
removal of all observations where PREVCHD == 1 (i.e. all patients with coronary heart disease at baseline)
created a new variable, cvd_dth signifying an outcome of cardiovascular disease OR death (i.e. if the patient had either CVD or DEATH, this new variable is 1, otherwise 0)
created a new variable, timeout, which calculates the number of days from the start of the study to cardiovascular disease, death, or loss to follow-up
created a new variable, logpdays, which is the log of timeout
created a new variable, nhosp, which is a simulated number of hospitalizations
data(cvdd)A data frame with 4240 rows and 31 variables:
Unique identification number for each participant.
Participant sex. 0 = Male, 1 = Female.
Serum Total Cholesterol (mg/dL).
Age at exam (years).
Systolic Blood Pressure (mean of last two of three measurements) (mmHg).
Diastolic Blood Pressure (mean of last two of three measurements) (mmHg).
Current cigarette smoking at exam. 0 = Not current smoker, 1 = Current smoker.
Number of cigarettes smoked each day. 0 = Not current smoker.
Body Mass Index, weight in kilograms/height meters squared.
Diabetic according to criteria of first exam treated or first exam with casual glucose of 200 mg/dL or more. 0 = Not a diabetic, 1 = Diabetic.
Use of Anti-hypertensive medication at exam. 0 = Not currently used, 1 = Current use.
Heart rate (Ventricular rate) in beats/min.
Casual serum glucose (mg/dL).
Level of completed education. 1 = 0-11 years, 2 = high school or GED, 3 = some college, 4 = college graduate or higher.
Prevalent Stroke. 0 = Free of disease, 1 = Prevalent disease.
Prevalent Hypertensive. Subject was defined as hypertensive if treated or if second exam at which mean systolic was >=140 mmHg or mean Diastolic >=90 mmHg. 0 = Free of disease, 1 = Prevalent disease.
Death from any cause. 0 = Did not occur during followup, 1 = Did occur during followup.
Angina Pectoris. 0 = Did not occur during followup, 1 = Did occur during followup.
Hospitalized Myocardial Infarction. 0 = Did not occur during followup, 1 = Did occur during followup.
Hospitalized Myocardial Infarction or Fatal Coronary Heart Disease. 0 = Did not occur during followup, 1 = Did occur during followup.
Angina Pectoris, Myocardial infarction (Hospitalized and silent or unrecognized), Coronary Insufficiency (Unstable Angina), or Fatal Coronary Heart Disease. 0 = Did not occur during followup, 1 = Did occur during followup.
Atherothrombotic infarction, Cerebral Embolism, Intracerebral Hemorrhage, or Subarachnoid Hemorrhage or Fatal Cerebrovascular Disease. 0 = Did not occur during followup, 1 = Did occur during followup.
Myocardial infarction (Hospitalized and silent or unrecognized), Fatal Coronary Heart Disease, Atherothrombotic infarction, Cerebral Embolism, Intracerebral Hemorrhage, or Subarachnoid Hemorrhage or Fatal Cerebrovascular Disease. 0 = Did not occur during followup, 1 = Did occur during followup.
Hypertensive. Defined as the first exam treated for high blood pressure or second exam in which either Systolic is 6 140 mmHg or Diastolic 6 90mmHg. 0 = Did not occur during followup, 1 = Did occur during followup.
Cardiovascular disease OR death. 0 = Did not occur during followup, 1 = Did occur during followup.
Number of days from the start of the study to cardiovascular disease, death, or loss to follow-up.
Participant was lost to follow-up before 24 months complete followup. 0 = no, 1 = yes
Casual serum glucose (mg/dL) after 6 years of follow-up
Natural log of timeout.
BMI category. 0 = Normal, 1 = Underweight, 2 = Overweight, 3 = Obese.
Simulated number of hospitalizations over 24 months, associated with age, sex, BMI, and diabetes (not collected in the Framingham study).
The National Heart, Lung, and Blood Institute of the National Institutes of Health developed a longitudinal, epidemiology-focused dataset using the Framingham Heart Study. The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of free living subjects in the community of Framingham, Massachusetts. The Framingham Heart Study was a landmark study in epidemiology in that it was the first prospective study of cardiovascular disease and identified the concept of risk factors and their joint effects. The study began in 1948 and 5,209 subjects were initially enrolled in the study. Participants have been examined biennially since the inception of the study and all subjects are continuously followed through regular surveillance for cardiovascular outcomes. Clinic examination data has included cardiovascular disease risk factors and markers of disease such as blood pressure, blood chemistry, lung function, smoking history, health behaviors, ECG tracings, Echocardiography, and medication use. Through regular surveillance of area hospitals, participant contact, and death certificates, the Framingham Heart Study reviews and adjudicates events for the occurrence of Angina Pectoris, Myocardial Infarction, Heart Failure, and Cerebrovascular disease. This dataset contains three clinic examinations and 20 year follow-up data on a large subset of the original Framingham cohort participants.
NOTE: This is a "teaching" dataset. Specific methods were employed to ensure an anonymous dataset that protects patient confidentiality; therefore, this dataset is inappropriate for publication purposes." The use of these data for the purposes of this package were approved on 11Mar2019 (request #7161) by NIH/NHLBI.